Group 1 - The core viewpoint of the article highlights the successful listing of N百奥, with an opening price of 58.00 yuan, reflecting a significant increase of 117.39% on its first trading day [2] - The company specializes in gene editing technology, providing innovative model animals and preclinical pharmaceutical research services, utilizing its proprietary RenMice platform for large-scale drug discovery and development [2] - N百奥 has developed into a comprehensive enterprise over the past decade, focusing on gene-edited model animal production, innovative model animal breeding, preclinical pharmacology and efficacy evaluation, and antibody drug discovery [2] Group 2 - The total issuance of shares for N百奥 was 47.50 million, with an online issuance of 11.46 million shares at a price of 26.68 yuan per share, resulting in a high issuance price-to-earnings ratio of 519.12, compared to the industry average of 39.31 [3] - The effective subscription number for the online issuance reached 6.03 million households, with a final winning rate of 0.02801388% [3] - The funds raised, totaling 1.267 billion yuan, will primarily be allocated to early drug development service platform construction, working capital, preclinical and clinical research projects, and antibody drug research and evaluation projects [3]
N百奥开盘上涨117.39%